We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

25 hedge funds and large institutions have $80.8M invested in ProQR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital inflows, than outflows

Capital inflows: $8.4M | Capital outflows: $5.24M

1.13% more ownership

Funds ownership: 33.55% → 34.68% (+1.1%)

0% more funds holding

Funds holding: 25 → 25 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.34M
2
PVI
Pura Vida Investments
New York
+$1.37M
3
JGC
J. Goldman & Co
New York
+$1.12M
4
Millennium Management
Millennium Management
New York
+$985K
5
Essex Investment Management
Essex Investment Management
Massachusetts
+$417K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.02M
2
Franklin Resources
Franklin Resources
California
-$952K
3
Sphera Funds Management
Sphera Funds Management
Israel
-$831K
4
SM
Sabby Management
Florida
-$529K
5
DCM
DAFNA Capital Management
California
-$300K

PRQR Hedge Fund Activity: Q2 2018 in Review

25 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2018, worth a combined $80.8M — up 146% from $32.9M a quarter earlier.

Fund positioning in PRQR was balanced in Q2 2018: 8 funds opened new positions, 8 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $3.34M. The largest seller was Artal Group, cutting an estimated $2.02M.

  • 25 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $80.8M of ProQR Therapeutics stock for Q2 2018, up 146% quarter-over-quarter.
  • 8 funds opened new ProQR Therapeutics positions in Q2 2018 and 8 closed out, a net change of 0 holders.
  • The largest ProQR Therapeutics buyer in Q2 2018 was Adage Capital Partners, an estimated $3.34M added.
  • The largest ProQR Therapeutics seller in Q2 2018 was Artal Group, an estimated $2.02M sold.

Based on aggregated 13F filings for Q2 2018.